Detailed price information for Pasithea Therapeutics Corp WT (KTTAW-Q) from The Globe and Mail including charting and trades.

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Learn how multichain biotherapeutics overcome manufacturing challenges with advanced expression vector design.